RenovoRx, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. RenovoRx is a clinical-stage biopharmaceutical company developing its TAMP local drug-delivery platform. Its lead candidate, RenovoGem, is in a Phase III trial for locally advanced pancreatic cancer. The company has not generated product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.257 million | $1.338 million |
| General and administrative expense | $1.219 million | $1.923 million |
| Total operating expenses | $2.476 million | $3.261 million |
| Operating loss | $2.476 million | $3.261 million |
| Net loss | $1.076 million | $3.257 million |
| Net loss per share, basic and diluted | $0.07 | $0.36 |
| Cash used in operating activities | $2.204 million | $2.706 million |
| Cash and cash equivalents | $4.389 million at March 31 | $1.173 million at December 31, 2023 |
All dollar amounts are U.S. dollars. Gross profit and margins are not applicable because the company reported no revenue. No conventional borrowings are presented on the balance sheet; liabilities included a $1.928 million common-warrant liability. Current liabilities were $1.093 million, and stockholders’ equity was $1.767 million at quarter-end. Accumulated deficit was $42.481 million.
Changes and notable items
- Operating expenses fell 24% year over year, primarily reflecting a 37% reduction in G&A; R&D decreased 6%.
- Net loss narrowed substantially, but included $1.363 million of noncash income from a decrease in the fair value of the April 2023 warrant liability. The fair-value gain is not operating revenue or cash generation.
- January’s private placement raised $6.1 million gross, issuing 6.13 million common shares and warrants to purchase additional shares. Common shares outstanding rose from 10.69 million at year-end to 16.87 million at March 31.
- On April 11, after quarter-end, the company completed another private placement for $11.1 million gross, issuing 6.96 million shares, a pre-funded warrant, and additional warrants. The filing gives differing estimates of offering expenses—approximately $1.5 million in the note and $1.1 million in MD&A.
- Nasdaq notified the company in February that it did not meet the minimum stockholders’ equity requirement. After the 2024 financings, Nasdaq notified it on April 17 that the deficiency was cured and listing compliance restored. Shares outstanding were 23,951,825 as of May 8.
Outlook, risks and other disclosures
- Management expects continued losses, negative operating cash flows and increasing expenses, particularly as it advances the Phase III program. It does not expect product revenue for the foreseeable future.
- Management stated that cash resources, including subsequent financing, are expected to fund needs for at least 12 months from the report’s issuance. Additional financing may still be needed; availability and acceptable terms are not assured.
- The TIGeR-PaC Phase III trial’s second interim analysis is expected to be triggered at 52 deaths, estimated for late 2024; data timing depends on analysis. The filing says the protocol and statistical-analysis modifications were submitted to FDA but had not been discussed with FDA.
- RenovoGem has orphan-drug designation for pancreatic and bile duct cancers. The company also describes potential future indications and collaboration opportunities, which remain subject to development, financing and regulatory risks.
- Management reported disclosure controls as ineffective and identified a material weakness in internal control over financial reporting, citing limited accounting staffing and expertise, inadequate formal review and segregation of duties, and IT access-control deficiencies. Remediation is underway and is not yet complete.
- No material legal proceedings were reported. The company’s headquarters lease is month-to-month. No formal financial guidance was provided.
Key facts for investors to verify
- Cash runway assumptions and the net proceeds and terms of the April 2024 financing, including the discrepancy in reported offering expenses.
- Phase III TIGeR-PaC enrollment, event timing, interim-analysis results and any FDA feedback on the modified study plan.
- Potential dilution from outstanding warrants and the substantial shares and warrants issued in 2024.
- Progress and effectiveness of the material-weakness remediation plan, and consistency of future financial reporting.
- Whether the warrant fair-value gain, a significant contributor to the lower reported net loss, is distinguished from underlying operating performance.